Background: Downstaging—reduction in late-stage incidence—has been proposed as an endpoint in randomized trials of multi-cancer early detection (MCED) tests. How downstaging depends on test performance and follow-up has been studied for some cancers but is understudied for cancers without existing screening and for MCED tests that include these cancer types.
van Rosmalen
As seen in:
Frontiers,
PNAS,
Biomed Central (BMC),
Critical Care,
Journal of Intensive Care,
Pediatrics
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with van
Contact van, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack